BioLineRx has received two notices of allowance from USPTO for BL-1021, an orally available small molecule for treating neuropathic pain. The first notice of allowance is issued for patent application claiming BL-1021's composition. Once ...
Tags: BL-1021, neuropathic pain, USPTO allowance